Sublingual allergen immunotherapy with a liquid birch pollen product in patients with seasonal allergic rhinoconjunctivitis with or without asthma by Pfaar, Oliver et al.
Rhinitis, sinusitis, and ocular allergy
Sublingual allergen immunotherapy with a liquid
birch pollen product in patients with seasonal
allergic rhinoconjunctivitis with or without
asthma
Oliver Pfaar, MD,a,b,c Claus Bachert, MD, PhD,d Piotr Kuna, MD,e Petr Panzner, MD, PhD,f
M!aria D"zupinov!a, MD, MSc, MBA,g Ludger Klimek, MD,c Maroesja J. van Nimwegen, PhD,h Johan D. Boot, PhD,h
Donghui Yu, PhD,h Dirk Jan E. Opstelten, PhD,h and Pieter-Jan de Kam, PhD, MBAh Marburg, Mannheim, and Wiesbaden,
Germany, Ghent, Belgium, Lodz, Poland, Pilsen, Czech Republic, Bardejov, Slovakia, and Leiden, The Netherlands
Background: Sublingual allergen immunotherapy (SLIT) has
been demonstrated to be both clinically efficacious and safe.
However, in line with the current regulatory guidance from the
European Medicines Agency, allergen immunotherapy (AIT)
products must demonstrate their efficacy and safety in pivotal
phase III trials for registration.
Objective: We sought to investigate the efficacy and safety of
sublingual high-dose liquid birch pollen extract (40,000 allergy
units native [AUN]/mL) in adults with birch pollen allergy.
Methods: A randomized, double-blind, placebo-controlled,
parallel-group multicenter trial was conducted in 406 adult
patients with moderate-to-severe birch pollen-induced allergic
rhinoconjunctivitis with or without mild-to-moderate controlled
asthma. Treatment was started 3 to 6 months before the birch
pollen season and continued during the season in 40 clinical
study centers in 5 European countries. For primary end point
assessment, the recommended combined symptom and
medication score of the European Academy of Allergy and
Clinical Immunology was used. Secondary end points included
quality-of-life assessments, immunologic parameters, and safety.
Results: Primary efficacy results demonstrated a significant
(P < .0001) and clinically relevant (32%) reduction in the
combined symptom and medication score compared with
placebo after 3 to 6 months of SLIT. Significantly better
rhinoconjunctivitis quality-of-life scores (P < .0001) and the
patient’s own overall assessment of his or her health status,
including the visual analog scale score (Euro Quality of
Life Visual Analogue Scale; P 5 .0025), were also
demonstrated. In total, a good safety profile of SLIT was
observed.
Conclusion: This study confirmed both the clinical efficacy and
safety of a sublingual liquid birch pollen extract in adults with
birch pollen allergy in a pivotal phase III trial (EudraCT:
2013-005550-30; ClinicalTrials.gov: NCT02231307). (J Allergy
Clin Immunol 2019;143:970-7.)
Key words: Birch pollen allergy, allergic rhinoconjunctivitis,
sublingual immunotherapy, allergen immunotherapy, efficacy, safety,
combined symptom and medication score, pivotal phase III trial,
quality of life
From athe Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhi-
nology and Allergy, University Hospital Marburg, Philipps-Universit€at Marburg; bthe
Department of Otorhinolaryngology, Head and Neck Surgery, Universit€atsmedizin
Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim; cthe Cen-
ter for Rhinology and Allergology, Wiesbaden; dthe Upper Airways Research Labora-
tory, University of Ghent; ethe Division of Internal Medicine, Asthma and Allergy,
Medical University of Lodz; fthe Department of Immunology andAllergology, Faculty
of Medicine in Pilsen, Charles University, Pilsen; gALIAN s.r.o. Ambulancia aler-
gol!ogie a klinickej imunol!ogie, Bardejov; and hHAL Allergy B.V., Leiden.
The results of this study were presented in part as poster presentations at annual
congresses of the European Academy of Allergy and Clinical Immunology (EAACI)
in Vienna, Austria, June 2016.
Sponsored by HAL Allergy B.V., Leiden, The Netherlands. The sponsor also paid for
open access of the article (online open publication).
Disclosure of potential conflict of interest: O. Pfaar reports grants and personal fees from
HALAllergyB.V. during the conduct of the study; grants and personal fees fromALK-
Abell!o, Allergopharma, Stallergenes Greer, HAL Allergy B.V./HAL Allergie GmbH,
Bencard Allergie GmbH/Allergy Therapeutics, and Lofarma; grants from Biomay,
Nuvo, and Circassia, grants and personal fees from Biotech Tools S.A.; grants and per-
sonal fees from Laboratorios LETI/LETI Pharma; personal fees fromNovartis Pharma
and MEDA Pharma; grants and personal fees from Anergis S.A.; personal fees from
Mobile Chamber Experts (a GA2LEN Partner), Pohl-Boskamp, and Indoor Biotech-
nologies; and grants fromGlaxoSmithKline all outside the submitted work. C. Bachert
reports grants and personal fees from HAL, ALK-Abell!o, Stallergenes Greer, Biotech
Tools, Novartis Pharma, Mylan, GlaxoSmithKline, Sanofi Aventis, and AstraZeneca.
P. Kuna reports personal fees from Adamed, Boehringer Ingelheim, AstraZeneca,
Chiesi, FAES, Berlin Chemie, Novartis, Polpharma, Allergopharma; personal fees
and nonfinancial support from ALK-Abell!o; and personal fees from HAL Allergy
outside the submitted work. P. Panzner reports personal fees from HALAllergy during
the conduct of the study and personal fees from ALK-Abell!o, Stallergenes Greer, As-
traZeneca, andASIT Biotech outside the submitted work. L. Klimek reports grants and
personal fees from ALK-Abell!o; personal fees from MEDA; grants and personal fees
from Novartis, Allergopharma, and Bionorica; personal fees from Boehringer Ingel-
heim; grants and personal fees fromGlaxoSmithKlinea and Lofarma; grants from Bio-
may, HAL, LETI, Roxall and Bencard outside the submitted work. M. J. van
Nimwegen, J. D. Boot, D. Yu, D. J. E. Opstelten, and P. J. de Kam were employees
of HALAllergy B.V. at the time of the conduct of the study. M. D"zupinov!a reports hav-
ing no relevant conflicts of interest.
Received for publication May 16, 2018; revised October 16, 2018; accepted for publica-
tion November 9, 2018.
Available online November 30, 2018.
Corresponding author: Oliver Pfaar, MD, Department of Otorhinolaryngology, Head and
Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Phil-
ipps-Universit€at Marburg, Germany. E-mail: oliver@pfaar.org.
The CrossMark symbol notifies online readers when updates have been made to the
article such as errata or minor corrections
0091-6749
! 2018 The Authors. Published by Elsevier Inc. on behalf of the American Academy of
Allergy, Asthma & Immunology. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
https://doi.org/10.1016/j.jaci.2018.11.018
970
Abbreviations used
ACQ: Asthma Control Questionnaire
AE: Adverse event
AIT: Allergen immunotherapy
ARC: Allergic rhinoconjunctivitis
AUN: Allergy units native
CSMS: Combined symptom and medication score
dMS: Daily medication score
dSS: Daily symptom score
EAACI: European Academy of Allergy and Clinical Immunology
EMA: European Medicines Agency
EQ-VAS: Euro Quality of Life Visual Analogue Scale
ITT: Intention to treat
PP: Per protocol
RQLQ: Rhinitis Quality of Life Questionnaire
SLIT: Sublingual allergen immunotherapy
TEAE: Treatment-emergent adverse event
Allergic rhinoconjunctivitis (ARC) is a symptomatic
disorder of the upper airways induced by an IgE-mediated
inflammatory response in sensitized subjects after allergen
exposure. Symptoms can be both nasal and ocular. ARC is
estimated to affect 10% to 25% of the global population, with a
considerable effect on quality of life.1,2 If left untreated, ARC is
considered one of the major risk factors for the development of
asthma.3-5 Treatment of ARC involves allergen avoidance,
pharmacotherapy, and allergen immunotherapy (AIT).1
Pharmacotherapy is intended for symptomatic treatment only.
However, despite adequate pharmacotherapeutic treatment, up
to every fifth patient still presents with uncontrolled nasal
and/or ocular symptoms, with a high impairment of quality of
life affecting work productivity, social interactions, and other
aspects of life.1,6
AIT is the only disease-modifying treatment option available
for patients with IgE-mediated allergic diseases, such as ARC,
and can be administered through several routes.7-10 With
sublingual administration, the allergen preparation is held
underneath the tongue to allow an immune-modulating effect
through the sublingual mucous membrane.11-13 Sublingual
allergen immunotherapy (SLIT) appears to be safe and well
tolerated.13 The efficacy and safety of SLIT in patients
with ARC induced by various inhalant allergens has been
confirmed in multiple clinical trials and recent systematic
reviews14-17 and is considered a viable alternative to
subcutaneous immunotherapy.7-10 In line with the regulatory
guidance of the European Medicines Agency (EMA),18
individual products in AIT have to demonstrate their clinical
efficacy in (pivotal) phase III trials subsequent to controlled
clinical trials (phase II) of the investigational product for
optimal dose determination.
Here we report a randomized, double-blind, placebo-
controlled, phase III study with an open-label safety extension
period in adults with birch pollen allergy. For SLIT, a high-dose
liquid birch pollen extract19 or placebowas used. Clinical efficacy
was analyzed by using primary and secondary end points, as rec-
ommended by the European Academy of Allergy and Clinical
Immunology (EAACI).20 This study is deemed pivotal regarding
the investigational product, as well as the end points used for ef-
ficacy assessment.
METHODS
Study design
This was a multicenter (n 5 40), randomized, double-blind, placebo-
controlled, parallel-group study performed preseasonally over 3 to 6 months
before the birch pollen season (September 2014 to May 2015) and continued
coseasonally during the pollen season including 406 adult patients (18-65 years),
followed by an open-label safety extension period over 6 months (June 2015 to
February 2016) including 343 patients. All participants had confirmed
moderate-to-severe persistent ARC according to the Allergic Rhinitis and its
Impact on Allergy classification1 for at least 2 consecutive years with or without
mild-to-moderate (controlled) asthma caused by sensitization to birch pollen.
Sensitization was confirmed based on positive skin prick test responses with a
mean wheal diameter of 3 mm or greater compared with that elicited by the
negative control (HAL Allergy B.V., Leiden, The Netherlands) and a positive
serum specific anti-birch IgE test result (concentration, >0.7 U/mL;
ImmunoCAP; Thermo Fischer, Phadia, Uppsala, Sweden) and clinical relevance
based on positive nasal provocation test results to birch pollen (HAL Allergy
B.V., Leiden, TheNetherlands). All patients independent of evidence of concom-
itant asthma needed an FEV1 of greater than 70% or a peak expiratory flow of
greater than 80% of predicted value to be included in the study. Patients had
to bewilling and capable of completing an e-diary during the birch pollen season.
Patients were excluded if they were sensitized and symptomatic to pets when
regularly exposed, subject to any subcutaneous immunotherapy or SLITwith the
investigational or a cross-reacting allergen within 5 years before the start of this
study, or had uncontrolled asthma or other respiratory diseases. Treatment
duration for patients in the double-blind part of the study was 6 to 9 months.
All patients provided written informed consent. The study protocol,
including all accompanying material, was approved by ethics committees
and competent authorities of the 5 participating countries (Germany, Belgium,
Poland, Czech Republic, and Slovakia). The trial was registered in the
EudraCT database as no. 2013-005550-30 and in the register of ClinicalTrials.
gov with identifier NCT02231307.
AIT
Eligible patients were randomly assigned to active/placebo treatment in a
1:1 manner stratified by the study site by using an Interactive Web Response
System.
For SLIT, a biologically standardized liquid allergen extract of birch pollen
(Betula verrucosa) in a glycerinated phosphate buffer was used and stabilized
with ε-aminocaproic acid in water for injection at a concentration of 40,000
allergy units native [AUN]/mL (active product; HAL Allergy B.V.). The Bet
v 1 content of the product is 0.4 mg/mL, as measured in comparison to the
EDQM–Bet v 1 reference preparation. Unlike the active preparation, placebo
did not contain any allergen. Regarding the excipient’s composition, active
and placebo preparations were the same, except for the caramel colorant
(E150c) added to placebo to ensure color blinding for the 2 treatments (pla-
cebo product; HAL Allergy B.V.).
Both study medications were taken sublingually once daily. After a daily
increase of 1 drop, themaintenance dosewas reached at 5 drops per day. Drops
were held for 2 to 3 minutes underneath the tongue and then swallowed. The
first dose (drop) of study medication was taken under the supervision of the
respective investigator.
Patient treatment compliance was checked based on the daily study
medication use entered into the e-diary and on returned used/unused bottles
or bottles claimed to be lost at the end of study site visits. In case of 25% or
more of the missing doses reported or absenteeism for greater than 7 days
during the actual pollen season, patients were considered protocol violators.
Assessment of efficacy
An overview of all assessments comprising the primary, secondary and
safety parameters and their timing is presented in Table I.
The primary end point was defined as the difference in mean combined
symptom and medication score (CSMS) between the active and placebo
treatment groups, as assessed during the birch pollen season. The CSMS is the
EAACI-recommended end point for pivotal studies, described in detail in the
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position paper of the EAACI.20 Briefly, CSMS is the sum of the daily symptom
score (dSS) plus daily medication score (dMS). The dSS is comprised of 6 in-
dividual symptom scores: 4 nasal symptoms (itchy nose, sneezing, runny nose,
and blocked nose) and 2 ocular symptoms (itchy/red eyes and watery eyes), all
rated on a scale of 0 to 3. The dSS was calculated as a mean of all nonmissing
dSS during the pollen season (range, 0-18) divided by the number of individual
symptoms (6 symptoms). Hence, the mean dSS can range from 0 to 3. The
dMS is based on the following scores: 0, no rescue medication; 1, antihista-
mines; 2, nasal corticosteroids; and 3, oral corticosteroids. This score was
again calculated as the average of the dMS during the pollen season. Conse-
quently, the mean dMS has a range of 0 to 3. The CSMS, which is equal to
the dSS plus dMS, has a range of 0 to 6 (see Appendix E1 in this article’s On-
line Repository at www.jacionline.org).20
Themean CSMSwas calculated from the sum of all daily CSMS during the
birch pollen season divided by the number of days in the birch pollen season.
For efficacy assessment, the respective mean CSMS of the active and placebo
groups were compared. A minimum clinically important CSMS difference of
23% was predefined in the study protocol and justified by using both clinical
and statistical considerations (data on file).
Each clinical site was allocated to a pollen station in the region/country,
which reported the pollen load daily. Determination of pollen counts was done
with volumetric pollen traps (Burkard Scientific, Uxbridge, United Kingdom).
The birch pollen season was predefined to start if birch pollen counts were 80
grains/m3 or greater per 24 hours on 3 of 5 consecutive days, with the first of
such days taken as the start day of the birch pollen season. The season ended
when birch pollen counts were less than 80 grains/m3 per 24 hours on 3 of 5
consecutive days, and the last of such days was the actual end day of the birch
pollen season.21 The total season could consist of several separate periods that
comply with this definition. The birch peak pollen season was defined as all
days with birch pollen counts of 500 grains/m3 or greater per 24 hours.
Secondary end points20 were mean CSMS during the birch peak pollen sea-
son; mean dSS and dMS separately during both the birch pollen and birch peak
pollen seasons; serum specific IgE, IgG, and IgG4 levels; and quality of life dur-
ing the birch pollen season and at the end of treatment. The latter was assessed
by using the (validated) disease-specificRhinitisQuality of LifeQuestionnaires
(RQLQ-S)22 for all patients, an Asthma Control Questionnaire (ACQ)23 for pa-
tients with concomitant asthma, and a visual analog scale (EQ-VAS)24 at base-
line during the pollen season and at the end of treatment (see Table I for details).
Serum specific IgE, IgG, and IgG4 levels to birch pollen extract (t3) and Bet v 1
major allergen (t215) were determined by using ImmunoCAP assays.
Safety data
The safety and tolerability of active versus placebo treatment was assessed
based on the number and severity of local and systemic reactions; adverse
events (AEs); laboratory parameters, such as hematology and blood chemis-
try; urinalysis; vital signs; physical examination; electrocardiography; lung
function testing; and use of concomitant medication.
Local reactions of oromucosal, ear, and gastrointestinal tract origin were
graded by severity (mild 5 no disruption of normal daily activities,
moderate 5 affect normal daily activities, and severe 5 inability to perform
daily activities), and systemic reactions graded according to EAACI criteria25
were assessed per treatment group. All serious AEs were coded by using the
Medical Dictionary for Regulatory Activities version, which was considered
current at the start of the trial (ie, Medical Dictionary for Regulatory Activities
17.0). Further differentiation of ‘‘drug-related’’ or ‘‘non–drug-related’’ and
treatment-emergent adverse events (TEAEs) was carried out. FEV1 was
measured 3 times with a spirometer or a universal range peak flow meter.
Concomitant medicationwas classified according to theWorld HealthOrganiza-
tion Drug Dictionary (March 2014) and assigned to anatomic therapeutic class.
Statistical analysis
A sample size of 170 patients per group was determined to provide a power
of 90% to detect a decrease of 25% in the active versus placebo groups,
assuming a mean CSMS of 1.30 in the placebo group and SD of 0.92 at a
significance level of .05 (2-sided). Based on an expected dropout rate of 15%, a
total of 200 patients per group were planned to be randomized.
Primary outcome analysis was carried out in the intention-to-treat (ITT)
population by using a mixed model with mean CSMS as a dependent
variable. It included treatment (active vs placebo) as a fixed factor and sites
pooled according to their assigned pollen station as a random factor. All tests
were 2-sided (a 5 .05). Analogously, this primary end point was also
analyzed in the per-protocol (PP) population. All secondary and exploratory
end points were analyzed based on mean estimates and 95% CIs of the
respective mean parameter for each treatment group, as well as for the
treatment difference. For percentages of well days and severe days, a
responder analysis using the ANOVA model with treatment as a fixed factor
was carried out. Well days were defined as days with no rescue medication
and a symptom score of no greater than 2,26 and severe days were defined as
days with a symptom score of 3 in any of the 6 rhinoconjunctivitis symp-
toms.27 Statistical analyses were conducted with SAS software (version
9.3; SAS Institute, Cary, NC).
RESULTS
Patients
Four hundred six patients were enrolled in one of the 2
treatment groups (208 to the active treatment and 198 to the
TABLE I. Overview of assessments of the primary, secondary, and safety parameters
Visits (timing)
Visit
1, 27 d
Visit
2, day 1
Visit
3, day 14
Visit
4, day 42
Visit
5, day 84
Visit 6,
February
2015
Visit 7,
April
2015
Visit 8,
Jun
2015
Visit 9,
14 days after
visit 8
Visit 10,
26 wk after
visit 9Assessments
Symptom score 1 allergy-related
medications (e-diary)
X X X X X
Quality-of-life questionnaires* X X X
Serum immunoglobulins
(IgE, IgG, IgG4)
X X X
Vital signs and weight! X X X X X
Physical examination X X X X X
Blood sampling safety X X X
Urinalysis safety X X X
Lung function X X X X
Electrocardiography X X
AE/concomitant medication
documentation eCRF
X X X X X X X X X X
eCRF, Electronic Case Report Form.
*Quality-of-life questionnaires were assessed twice during the pollen season on the e-diary on April 15 and 30; ACQ questionnaires were assessed at visits 2, 7, and 8.
!Weight was only assessed during the visit 1 screening; at the other visits, only blood pressure was measured.
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placebo group, see Fig 1, CONSORT flow diagram). Demo-
graphics and baseline characteristics of the study population are
depicted in Table II. Demographic and baseline characteristics
did not show notable differences between placebo and active
treatment.
Thirty-two patients terminated the study prematurely (Fig 1).
The main reason for early termination was the development of
AEs. The ITT population for primary efficacy evaluation con-
sisted of 357 patients. As specified in the study protocol, the
ITT population includes all patients who are randomized and
received at least 1 dose of study medication and for whom at least
1 postbaseline (postscreening) measurement for the primary effi-
cacy parameter is available.
A total of 343 patients who completed the double-blind phase
of the study were included in the open-label safety extension
period and treated with the active product exclusively.
Demographic and baseline characteristics (Table II) did not
show notable differences between active and placebo treatment
nor were any relevant differences between treatment groups
identified in relation to (1) allergy medical history, (2) asthma
FIG 1. CONSORT flow diagram: overview of patient disposition in the double-blind part of the study and the
safety extension study. SAF, Safety population.
J ALLERGY CLIN IMMUNOL
VOLUME 143, NUMBER 3
PFAAR ET AL 973
medical history, (3) serum specific IgE levels, (4) lung function
and nasal provocation test results, (5) physical examination re-
sults and concomitant medication, and (6) compliance (data
not shown).
Efficacy
Primary end point. The primary end point analysis showed
a statistically significant (P < .0001) difference of 32% for the
CSMS during the pollen season in the active group compared
with that in the placebo group in the ITT population (Fig 2 and
Table III). Supportive of this result was a CSMS reduction in
the PP population, also decreasing by 32% (P < .0001) in the
active versus placebo treatment groups during birch pollen expo-
sure. Additional sensitivity analysis with all randomized subjects
with multiple imputation of missing values by using the method
of unrestricted random sampling with replacement (ie, missing
data of the placebo group were replaced by observed data of the
placebo group and vice versa) showed consistent results
(P < .0001). The same was true for the 2 worst-case scenarios
like ‘‘all patients with missing values got data of the placebo ef-
fect’’ and ‘‘patients from active group with missing values got
data of the placebo effect, patients from placebo group with
missing values got data of the effect of active treatment’’
(P < .0001 and P < .001, respectively). The differences were still
greater than the predefined minimal clinically relevant difference
and did not change the conclusion for the treatment effect.
Secondary end points. During the peak pollen season, a
statistically significant reduction in CSMS of 38% (P <.0001) for
the active group (ITT population) could be detected and was
almost identical to the decrease in CSMS, as determined in the
PP set of patients (39%; P < .0001). Also, evaluation of CSMS
subcategories (ie symptom, medication, and nasal and ocular
symptom scores) showed a statistically significant reduction in
the active patient set during both the pollen season and the peak
pollen season (Fig 3 for the pollen season in the ITT population).
Also, the percentage of well days and severe days showed
consistent statistically significant improvement in the actively
treated group, with 15% more well days and 5% less severe days
during the pollen season. The result of this analysis was similar
irrespective of whether the PP or ITT populations were assessed.
Baseline RQLQ-S scores were similar for both treatment
groups (mean value: placebo 5 0.41 vs active 5 0.47). During
the pollen season, RQLQ-S scores increased in both groups,
corresponding to a reduced quality of life caused by increased
rhinitis burden. However, after active treatment, the mean RQLQ-
S score increase from a baseline of 0.55 (SE, 0.09) was less
pronounced compared with the RQLQ-S score increase of 1.10
(SE, 0.09) observed after placebo. This corresponds to a
significantly (P < .0001) improved rhinoconjunctivitis quality of
life in actively treated patients of the ITT population (difference,
20.55; 95%CI,20.77 to20.33). Analysis of RQLQ-S scores for
the PP population yielded similar statistically significant results.
At the end of treatment (after the end of the pollen season),
RQLQ-S scores in both treatment groups returned to similar
values (mean RQLQ-S score: active, 0.42 [SE, 0.08]; placebo,
0.50 [SE 0.08]).
A treatment effect on general health-related quality of life
could also be shown. During the pollen season, a statistically
significant improvement in change from baseline EQ-VAS scores
between active and placebo group patients (ITT population) was
apparent (mean EQ-VAS score active,23.95 [SE, 1.27]; placebo,
28.72 [SE, 1.27]; difference, 4.77 [95% CI, 1.68-7.86];
P5 .0025). Assessment of the PP population demonstrated com-
parable results. At baseline and at the end of the study (ie, outside
the pollen season), general health status was not different between
the groups. Assessment of ACQ scores in patients with birch
pollen–induced concomitant asthma (subgroup of 27% of all pa-
tients) did not show statistically significant differences between
treatment groups, irrespective of whether the ITT or PP popula-
tions were considered, which can be explained by the relatively
mild asthma symptoms, as demonstrated by the relatively low
mean ACQ score at baseline (0.42 [SD, 0.58]) and by the fact
that asthma had to be controlled during the trial.
TABLE II. Summary statistics of demographics and baseline
characteristics (safety population)
Parameter name
Placebo
(n 5 198)
Active (40,000
AUN/mL
[n 5 208]) All (n 5 406)
Sex, no. (%)
Female 118 (59.6) 106 (51.0) 224 (55.2)
Male 80 (40.4) 102 (49.0) 182 (44.8)
Race, no. (%)
Black 1 (0.5) 1 (0.2)
White 195 (98.5) 207 (99.5) 402 (99.0)
Hispanic 1 (0.5) 1 (0.5) 2 (0.5)
Other 1 (0.5) 1 (0.2)
Age (y)
No. 198 208 406
Mean (SD) 36.69 (10.77) 37.48 (11.43) 37.10 (11.11)
Median
(minimum-
maximum)
36.00 (18.0-61.0) 37.00 (18.0-65.0) 36.00 (18.0-65.0)
BMI (kg/m2)
No. 198 208 406
Mean (SD) 25.02 (4.01) 25.32 (4.14) 25.18 (4.07)
Median
(minimum-
maximum)
24.54 (17.0-39.2) 24.84 (17.9-37.7) 24.71 (17.0-39.2)
Other allergies
No 108 (54.5) 103 (49.5) 211 (52.0)
Yes 90 (45.5) 105 (50.5) 195 (48.0)
FIG 2. Mean CSMS during the birch pollen season for patients in the
placebo and active treatment groups (ITT).
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Immunologic parameters, such as levels of specific IgE, IgG,
and IgG4 to both the birch pollen extract and Bet v 1, were found
to increase significantly only in the active group. No significant
changes were observed in the placebo group. Levels of specific
IgE increased significantly after 12 weeks (2.3-fold change from
baseline, P < .0001) in the active treatment group and decreased
to a level just above the screening value at the end of the study.
Levels of specific IgG and IgG4 (Fig 4 for IgG4) increased signif-
icantly after 12 weeks of treatment (3.7-fold change from base-
line for specific IgG4, P <.0001) and further increased at the end
of the study (6.7-fold change from baseline for specific IgG4,
P < .0001). These results were similar whether analyzed in the
ITT or PP populations.
Safety
The safety population included all patients who received study
medication at least once.
Exposure to the study medication during the double-blind
period of the study did not differ between the placebo and active
groups. Compliance for the total period was high (about 99%), as
indicated by the number of reported days without intake of study
medication (ie, 2.7 6 7.2 days for the active group and
2.1 6 4.5 days for the placebo group).
During the open-label extension period of the study, exposure
to the study medication was 174.9 6 41.7 days for formerly
placebo-treated patients and 187.3 6 13.2 days for patients
continuing active treatment.
Local and systemic TEAEs for the double-blind
period of the study. In total, 342 local reactions occurred in
165 (40.6%) patients. One hundred twenty-three (59.6%) patients
of the active group reported a total of 271 local reactions
compared with 42 (21.2%) patients of the placebo group reporting
71 local reactions. In total, 83.0% of all reactions were of mild
intensity. Four (1.9%) patients of the active treatment group
experienced at least 1 severe local reaction (Table IV).
A total of 92 systemic reactions were reported by 51 (12.6%)
patients. Of these, 73 reactions occurred in the active group (in 37
[17.8%] patients) compared with 19 reactions (in 14 [7.1%]
patients) for the placebo group. The TEAEs in the active group
were of grade 0 in 2 (1%) patients, grade I in 31 (14.9%) patients,
grade II in 3 (1.4%) patients, and grade III in 1 (0.5%) patients; in
the placebo group, TEAEs were of grade 0 in 1 (0.5%) patient,
grade I in 12 (6.1%) patients, and grade II in 1 (0.5%) patient. Two
patients receiving active treatment reported a drug-related serious
AE: 1 angioedema (grade III) and 1 throat edema (grade II). Both
resolved immediately after treatment. The patient with angioe-
dema was withdrawn from the study. In the patient experiencing
throat edema, a temporary dose adaptation was deemed
necessary.
Local and systemic TEAEs for the open-label exten-
sion period of the study. In total, 123 of 343 patients
included in the open-label extension period of the study reported a
local reaction, 88 of whom belonged to the former placebo group.
Most local reactions were of mild-to-moderate intensity (>97%).
Fifteen patients reported mild systemic reactions. No grade IV
systemic TEAEs occurred, and no suspected unexpected serious
adverse reactions have been reported. Regarding clinical and
laboratory safety parameters, no safety issues were observed.
DISCUSSION
To our knowledge, this is the first report of a SLIT product for
patients with birch pollen allergy undergoing the full develop-
ment program, including the current pivotal phase III study,
according to the EMA’s recommendations.18 In a preceding dose-
range finding and tolerability (phase II) study, the dose of 40,000
AUN/mL was determined to be optimal for this birch SLIT prod-
uct.19 Moreover, this is the first report of a phase III trial on clin-
ical efficacy of an AIT product using the CSMS recommended by
the EAACI.20
For this birch SLIT product, unequivocal evidence for signif-
icant and clinically relevant efficacy was shown. This effect could
FIG 3. Mean Individual symptom, medication, and nasal and ocular symp-
tom scores during the birch pollen season for patients in the placebo (dark
blue) and active (light blue; ITT population) treatment groups. SS, Symp-
tom score.
FIG 4. Mean fold change from baseline in serum specific IgG4 (birch pollen,
t3; Bet v 1, t215) levels for placebo and active treatment (ITT population).
TABLE III. Primary end point analysis: CSMSs during the pollen season (ITT population)
Parameter Placebo (n 5 178), mean (SE) Active (n 5 179), mean (SE) Active 2 placebo difference (95% CI), mean (SE) P value
CSMS 1.45 (0.08) 1.00 (0.08) 20.46 (20.66 to 20.26) <.0001
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be demonstrated after only 3 to 6 months of preseasonal followed
by 3 months of coseasonal treatment. Results of the primary end
point analysis were consistently supported by results obtained for
all secondary end points, irrespective of whether analysis
occurred during the whole pollen season or the peak pollen
season or considering the ITT or PP population. The observed
treatment effect size of 32% exceeds the recommendations of the
World Allergy Organization regarding the minimal clinically
relevant efficacy of 20%.28 This decrease in CSMS in the active
group was accompanied by a significantly improved quality of
life (expressed by both RQLQ-S and EQ-VAS) compared with
that seen in placebo-treated patients.
Immunologic changes during AIT, which are clearly indicative
of efficacy, are titers of specific IgG and IgG4 antibodies to birch
pollen extract and Bet v 1. Both were significantly increased in the
active group and remained unchanged in the placebo group. IgG4
production has recently been shown to be confined to IL-10–
secreting regulatory B cells, which are believed to be essentially
involved in the development of allergen tolerance,29 and has also
been emphasized as a valuable biomarker of adherence to
AIT.30,31 Local and systemic adverse reactions were mainly of
mild intensity and well controlled. Results of recent systemic re-
views on high-dose SLIT16,17,32 confirm our finding that local re-
actions are common and much more frequent in the active
compared with placebo groups and that the frequency and severity
of TEAEs decrease with ongoing treatment.
Direct comparison of clinical trial results with different AIT
products in general and for SLIT products especially has been
hampered greatly by the remarkable heterogeneity in outcome
parameters for efficacy used in such studies, let alone the
divergent study designs.33,34 In the EMA guidelines,18 which
came into effect in 2009, recommendations were published on
how to build primary end points based on combined symptom
medication scores. These recommendations were taken up by
an EAACI task force and transformed into a CSMS based on
equal weight, respectively.20 Data presented here with this new
scoring system verify its ease of use, its responsiveness over
time, and its fitness for the purpose of measuring disease-
influencing elements deemed associated with ARC. Therefore it
can be recommended as a standard in future clinical trials on
AIT products for the treatment of ARC.
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Clinical implications: Data presented in this article demon-
strate the efficacy and safety of this liquid SLIT product in pa-
tients with birch allergy with rhinoconjunctivitis with or
without asthma based on EAACI recommended end points.
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